CART Cell Toxicities: New Insight into Mechanisms and Management
T cells genetically engineered with chimeric antigen receptors (CART) have become a potent class of cancer immunotherapeutics. Numerous clinical trials of CART cells have revealed remarkable remission rates in patients with relapsed or refractory hematologic malignancies. Despite recent clinical suc...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAABRON PRESS
2020-11-01
|
| Series: | Clinical Hematology International |
| Subjects: | |
| Online Access: | https://www.atlantis-press.com/article/125946348/view |